Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma

A University of Chicago phase II consortium study

Sridhar Mani, J. W. Kugler, D. F. Sciortino, J. C. Garcia, R. H. Ansari, R. Humerickhouse, F. Michelassi, M. C. Posner, K. L. Shulman, R. L. Schilsky, M. List, E. E. Vokes, S. Benner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background/objectives: Uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) has broad anti-tumor activity for cancers arising from the gastrointestinal tract. However, there are no published data regarding the efficacy of leucovorin-modulated UFT in patients with pancreatic cancer. The objective of this trial was to determine the activity and evaluate the toxicity of UFT plus oral calcium leucovorin in patients with advanced pancreatic adenocarcinoma. Patients and methods: Fourteen patients with advanced measurable adenocarcinoma of the pancreas were enrolled onto the trial. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided doses every eight hours for 28 days repeated every 35 days. Objective tumor response was evaluated after two courses of therapy. Results: Fourteen patients were evaluable for response and toxicity. No objective responses were seen. The median (range) time to progression and survival were 14 (1.6-37), and 15 (1.9- 62) weeks, respectively. Toxicity was mild with severe (grade 3 or 4)hyperbilirubinemia, pain, diarrhea, transaminitis, venous thrombus, weakness, renal failure, confusion, and edema/ascites seen in three (21%), one (7%), two (14%), one (7%), one (7%), one (7%), one (7%), one (7%), and two (14%) patients, respectively. Conclusion: In the 14 patients evaluable, UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days did not demonstrate anti-tumor activity against advanced pancreatic adenocarcinoma; however, this oral regimen was well tolerated and devoid of neutropenia, significant oral mucositis or diarrhea.

Original languageEnglish (US)
Pages (from-to)1035-1037
Number of pages3
JournalAnnals of Oncology
Volume9
Issue number9
DOIs
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Tegafur
Uracil
Leucovorin
Adenocarcinoma
Diarrhea
Confusion
Neoplasms
Stomatitis
Gastrointestinal Neoplasms
Hyperbilirubinemia
Pancreatic Carcinoma
Neutropenia
Pancreatic Neoplasms
Ascites
Renal Insufficiency
Pancreas
Edema
Thrombosis
Pain
Survival

Keywords

  • Ftorafur
  • Leucovorin
  • Pancreatic cancer
  • Uracil

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma : A University of Chicago phase II consortium study. / Mani, Sridhar; Kugler, J. W.; Sciortino, D. F.; Garcia, J. C.; Ansari, R. H.; Humerickhouse, R.; Michelassi, F.; Posner, M. C.; Shulman, K. L.; Schilsky, R. L.; List, M.; Vokes, E. E.; Benner, S.

In: Annals of Oncology, Vol. 9, No. 9, 09.1998, p. 1035-1037.

Research output: Contribution to journalArticle

Mani, S, Kugler, JW, Sciortino, DF, Garcia, JC, Ansari, RH, Humerickhouse, R, Michelassi, F, Posner, MC, Shulman, KL, Schilsky, RL, List, M, Vokes, EE & Benner, S 1998, 'Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study', Annals of Oncology, vol. 9, no. 9, pp. 1035-1037. https://doi.org/10.1023/A:1008427231049
Mani, Sridhar ; Kugler, J. W. ; Sciortino, D. F. ; Garcia, J. C. ; Ansari, R. H. ; Humerickhouse, R. ; Michelassi, F. ; Posner, M. C. ; Shulman, K. L. ; Schilsky, R. L. ; List, M. ; Vokes, E. E. ; Benner, S. / Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma : A University of Chicago phase II consortium study. In: Annals of Oncology. 1998 ; Vol. 9, No. 9. pp. 1035-1037.
@article{e3cf6e4e36ba427d9f2cbd177be8389d,
title = "Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study",
abstract = "Background/objectives: Uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) has broad anti-tumor activity for cancers arising from the gastrointestinal tract. However, there are no published data regarding the efficacy of leucovorin-modulated UFT in patients with pancreatic cancer. The objective of this trial was to determine the activity and evaluate the toxicity of UFT plus oral calcium leucovorin in patients with advanced pancreatic adenocarcinoma. Patients and methods: Fourteen patients with advanced measurable adenocarcinoma of the pancreas were enrolled onto the trial. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided doses every eight hours for 28 days repeated every 35 days. Objective tumor response was evaluated after two courses of therapy. Results: Fourteen patients were evaluable for response and toxicity. No objective responses were seen. The median (range) time to progression and survival were 14 (1.6-37), and 15 (1.9- 62) weeks, respectively. Toxicity was mild with severe (grade 3 or 4)hyperbilirubinemia, pain, diarrhea, transaminitis, venous thrombus, weakness, renal failure, confusion, and edema/ascites seen in three (21{\%}), one (7{\%}), two (14{\%}), one (7{\%}), one (7{\%}), one (7{\%}), one (7{\%}), one (7{\%}), and two (14{\%}) patients, respectively. Conclusion: In the 14 patients evaluable, UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days did not demonstrate anti-tumor activity against advanced pancreatic adenocarcinoma; however, this oral regimen was well tolerated and devoid of neutropenia, significant oral mucositis or diarrhea.",
keywords = "Ftorafur, Leucovorin, Pancreatic cancer, Uracil",
author = "Sridhar Mani and Kugler, {J. W.} and Sciortino, {D. F.} and Garcia, {J. C.} and Ansari, {R. H.} and R. Humerickhouse and F. Michelassi and Posner, {M. C.} and Shulman, {K. L.} and Schilsky, {R. L.} and M. List and Vokes, {E. E.} and S. Benner",
year = "1998",
month = "9",
doi = "10.1023/A:1008427231049",
language = "English (US)",
volume = "9",
pages = "1035--1037",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma

T2 - A University of Chicago phase II consortium study

AU - Mani, Sridhar

AU - Kugler, J. W.

AU - Sciortino, D. F.

AU - Garcia, J. C.

AU - Ansari, R. H.

AU - Humerickhouse, R.

AU - Michelassi, F.

AU - Posner, M. C.

AU - Shulman, K. L.

AU - Schilsky, R. L.

AU - List, M.

AU - Vokes, E. E.

AU - Benner, S.

PY - 1998/9

Y1 - 1998/9

N2 - Background/objectives: Uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) has broad anti-tumor activity for cancers arising from the gastrointestinal tract. However, there are no published data regarding the efficacy of leucovorin-modulated UFT in patients with pancreatic cancer. The objective of this trial was to determine the activity and evaluate the toxicity of UFT plus oral calcium leucovorin in patients with advanced pancreatic adenocarcinoma. Patients and methods: Fourteen patients with advanced measurable adenocarcinoma of the pancreas were enrolled onto the trial. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided doses every eight hours for 28 days repeated every 35 days. Objective tumor response was evaluated after two courses of therapy. Results: Fourteen patients were evaluable for response and toxicity. No objective responses were seen. The median (range) time to progression and survival were 14 (1.6-37), and 15 (1.9- 62) weeks, respectively. Toxicity was mild with severe (grade 3 or 4)hyperbilirubinemia, pain, diarrhea, transaminitis, venous thrombus, weakness, renal failure, confusion, and edema/ascites seen in three (21%), one (7%), two (14%), one (7%), one (7%), one (7%), one (7%), one (7%), and two (14%) patients, respectively. Conclusion: In the 14 patients evaluable, UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days did not demonstrate anti-tumor activity against advanced pancreatic adenocarcinoma; however, this oral regimen was well tolerated and devoid of neutropenia, significant oral mucositis or diarrhea.

AB - Background/objectives: Uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) has broad anti-tumor activity for cancers arising from the gastrointestinal tract. However, there are no published data regarding the efficacy of leucovorin-modulated UFT in patients with pancreatic cancer. The objective of this trial was to determine the activity and evaluate the toxicity of UFT plus oral calcium leucovorin in patients with advanced pancreatic adenocarcinoma. Patients and methods: Fourteen patients with advanced measurable adenocarcinoma of the pancreas were enrolled onto the trial. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided doses every eight hours for 28 days repeated every 35 days. Objective tumor response was evaluated after two courses of therapy. Results: Fourteen patients were evaluable for response and toxicity. No objective responses were seen. The median (range) time to progression and survival were 14 (1.6-37), and 15 (1.9- 62) weeks, respectively. Toxicity was mild with severe (grade 3 or 4)hyperbilirubinemia, pain, diarrhea, transaminitis, venous thrombus, weakness, renal failure, confusion, and edema/ascites seen in three (21%), one (7%), two (14%), one (7%), one (7%), one (7%), one (7%), one (7%), and two (14%) patients, respectively. Conclusion: In the 14 patients evaluable, UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days did not demonstrate anti-tumor activity against advanced pancreatic adenocarcinoma; however, this oral regimen was well tolerated and devoid of neutropenia, significant oral mucositis or diarrhea.

KW - Ftorafur

KW - Leucovorin

KW - Pancreatic cancer

KW - Uracil

UR - http://www.scopus.com/inward/record.url?scp=7844236416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844236416&partnerID=8YFLogxK

U2 - 10.1023/A:1008427231049

DO - 10.1023/A:1008427231049

M3 - Article

VL - 9

SP - 1035

EP - 1037

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -